• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 16, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Senescent cell research moves into human trials

Bioengineer by Bioengineer
January 7, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Rochester, Minn. — Mayo Clinic researchers, along with collaborators from Wake Forest School of Medicine and the The University of Texas Health Sciences Center at San Antonio, have published findings from a safety and feasibility clinical trial on the removal of senescent cells from a small group of patients with pulmonary fibrosis. The findings appear in EBioMedicine.

While lung function, clinical test outcomes, frailty levels and overall health among the patients did not change, all 14 participants showed clinically meaningful improvement in physical function in nine doses over three weeks. That ability was measured in four tests: gait speed, walking speed in six minutes, a chair rise test and a score related to a bank of physical function tests.

“This was a short safety trial to determine if we should move ahead with actual large-scale human trials,” says senior author James Kirkland, M.D., Ph.D., head of the Robert and Arlene Kogod Center on Aging. “It’s important to emphasize that, while some measurable improvement was noted in all the participants, this is simply the start of human studies. We don’t know what lies ahead.” Senescent or semidormant cells (sometimes called “zombie cells”) form in many areas of the body and cause aspects of aging and frailty, ranging from osteoporosis to diabetes and muscle weakness. In this case, researchers are focusing on idiopathic pulmonary fibrosis, a progressive and fatal condition that is related to senescent cells. The researchers used a drug called a senolytic – dasatinib plus quercetin, an open-label drug, to clear the senescent cells.

“We are studying the effectiveness of this and other senolytic drugs, but that does not mean that these should be used by patients or prescribed by physicians for any off-label conditions,” says Dr. Kirkland. “I want to emphasize that no one should take these drugs. This research is only beginning.”

###

Co-first authors of the article are Jamie Justice, Ph.D., Wake Forest School of Medicine, and Anoop Nambiar, M.D., UT Health. Other collaborating institutions were the South Texas Veterans Health Care System and the University of Central Florida. The research was funded by the National Institutes of Health; the Claude Pepper Older Americans Independence Centers; The Connor Group; Robert and Theresa Ryan; John and Virginia Kunkel; and the Noaber, Ted Nash Long Life and Glenn Foundations. The research was not supported by any private industry or other for-profit agencies. The Mayo researchers have a financial interest in this research. Patents on senolytic drugs are held by Mayo Clinic.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network.

Media Contact
Bob Nellis
newsbureau@mayo.edu
507-284-5005
https://newsnetwork.mayoclinic.org/discussion/senescent-cell-research-moves-into-human-trials-2/

Tags: Clinical TrialsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

AI Guidance Enables Nonexperts to Capture Diagnostic Echocardiograms in Controlled Settings

AI Guidance Enables Nonexperts to Capture Diagnostic Echocardiograms in Controlled Settings

November 16, 2026
Prenatal Stress Shows No Link to Epigenetic Age Acceleration at Birth

Prenatal Stress Shows No Link to Epigenetic Age Acceleration at Birth

November 16, 2026

Transcriptional Signatures in Monkeys Linked to MECP2-Related Brain Dysfunction in Autism

November 16, 2026

Childhood Plasma miRNAs Indicate Neurodevelopmental Delay Linked to Prenatal Alcohol Exposure

November 16, 2026
Please login to join discussion

POPULAR NEWS

  • Childhood Plasma miRNAs Indicate Neurodevelopmental Delay Linked to Prenatal Alcohol Exposure

    Childhood Plasma miRNAs Indicate Neurodevelopmental Delay Linked to Prenatal Alcohol Exposure

    29 shares
    Share 12 Tweet 7
  • OCD Patients Show Heightened Sensitivity to Local Evidence Despite Lower Overall Confidence

    29 shares
    Share 12 Tweet 7
  • Prenatal Anxiety and Depression Predict Distinct Infant Cerebellar Asymmetry Patterns

    29 shares
    Share 12 Tweet 7
  • Probing combined with platelet-rich plasma improved moderate-to-severe meibomian dysfunction in trial

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

AI Guidance Enables Nonexperts to Capture Diagnostic Echocardiograms in Controlled Settings

Prenatal Stress Shows No Link to Epigenetic Age Acceleration at Birth

Transcriptional Signatures in Monkeys Linked to MECP2-Related Brain Dysfunction in Autism

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.